Survodutide 2mg

Quickstart Highlights

Survodutide (BI 456906) is a dual glucagon/GLP‑1 receptor agonist investigated for obesity and related metabolic conditions. Clinical trials used once‑weekly subcutaneous injections with dose‑dependent weight loss during a 20‑week escalation and maintenance thereafter[1]. Gastrointestinal effects (nausea/diarrhea) were the most common adverse events and can be mitigated with slower escalation strategies[3], with overall safety acceptable in studied populations[1][12].

Reconstitute: Add 2.0 mL bacteriostatic water → ~5.00 mg/mL (~5000 mcg/mL). (2.0 mL chosen to keep higher weekly doses ≤1.0 mL per injection.)
Typical weekly range: 600–4800 mcg once weekly with gradual titration anchored to clinical trial ranges[1][3]. Open source
Insulin‑syringe math: At ~5.00 mg/mL, 1 unit = 0.01 mL ≈ 50 mcg on a U‑100 insulin syringe.
Storage: Lyophilized: freeze at −20 °C (−4 °F). After reconstitution: refrigerate at 2–8 °C (35.6–46.4 °F); protect from light; avoid repeated freeze–thaw cycles.

Dosing & Reconstitution Guide

Educational guide for reconstitution and weekly dosing (subcutaneous, once weekly per clinical literature[1][3]).

Standard / Gradual Approach (2.0 mL = ~5.00 mg/mL)

Week	Daily Dose (mcg)	Units (per injection) (mL)
Weeks 1–4	600 mcg	12 units (0.12 mL)
Weeks 5–8	1200 mcg	24 units (0.24 mL)
Weeks 9–12	1800 mcg	36 units (0.36 mL)
Weeks 13–16	2400 mcg	48 units (0.48 mL)
Weeks 17–20 (optional escalation)	3600 mcg	72 units (0.72 mL)
Weeks 21–24 (optional escalation)	4800 mcg	96 units (0.96 mL)

Frequency: Inject once weekly subcutaneously. The column labeled “Daily Dose” reflects the per‑injection (weekly) dose because this regimen is weekly, not daily. Clinical trials escalated weekly doses over ~20 weeks before maintenance; slower escalations may reduce GI adverse events[1][3].

Reconstitution Steps

Reference-derived details for Survodutide 2mg.

Draw 2.0 mL bacteriostatic water with a sterile syringe.
Inject slowly down the vial wall; avoid foaming.
Gently swirl/roll until dissolved (do not shake).
Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.

Supplies Needed

Plan based on an 8–16 week once‑weekly titration anchored to clinical trial dosing ranges[1].

Peptide Vials (Survodutide, 10 mg each):
Peptide Vials (Survodutide, 10 mg each):: 8 weeks (0.6→1.2 mg): total ≈ 7.2 mg → 1 vial
Peptide Vials (Survodutide, 10 mg each):: 12 weeks (adds 1.8 mg phase): total ≈ 14.4 mg → 2 vials
Peptide Vials (Survodutide, 10 mg each):: 16 weeks (adds 2.4 mg phase): total ≈ 24.0 mg → 3 vials
Insulin Syringes (U‑100):
Insulin Syringes (U‑100):: Per week: 1 syringe (1 injection/week)
Insulin Syringes (U‑100):: 8 weeks: 8 syringes
Insulin Syringes (U‑100):: 12 weeks: 12 syringes
Insulin Syringes (U‑100):: 16 weeks: 16 syringes
Bacteriostatic Water (10 mL bottles): Use ~2.0 mL per vial.
Bacteriostatic Water (10 mL bottles): Use ~2.0 mL per vial.: 8 weeks (1 vial): 2.0 mL → 1 × 10 mL bottle
Bacteriostatic Water (10 mL bottles): Use ~2.0 mL per vial.: 12 weeks (2 vials): 4.0 mL → 1 × 10 mL bottle
Bacteriostatic Water (10 mL bottles): Use ~2.0 mL per vial.: 16 weeks (3 vials): 6.0 mL → 1 × 10 mL bottle
Alcohol Swabs: One for the vial stopper + one for the injection site per dose.
Alcohol Swabs: One for the vial stopper + one for the injection site per dose.: Per week: 2 swabs
Alcohol Swabs: One for the vial stopper + one for the injection site per dose.: 8 weeks: 16 swabs → recommend 1 × 100‑count box
Alcohol Swabs: One for the vial stopper + one for the injection site per dose.: 12 weeks: 24 swabs → recommend 1 × 100‑count box
Alcohol Swabs: One for the vial stopper + one for the injection site per dose.: 16 weeks: 32 swabs → recommend 1 × 100‑count box

Protocol Overview

Concise summary of the once‑weekly regimen.

Goal: Support clinically meaningful weight reduction and metabolic improvements over time[1][3]. Open source
Schedule: Weekly subcutaneous injections for 8–12 weeks (optional extension to 16–24 weeks depending on tolerance and goals)[1]. Open source
Dose Range: 600–4800 mcg weekly (0.6–4.8 mg), escalating as tolerated within trial‑tested ranges[1][3]. Open source
Reconstitution: 2.0 mL per 10 mg vial (~5.00 mg/mL) to keep higher weekly doses ≤1.0 mL.
Storage: Lyophilized frozen; reconstituted refrigerated; avoid freeze–thaw cycles.

Dosing Protocol

Suggested once‑weekly titration approach informed by clinical studies.

Start: 600 mcg once weekly.
Titrate: Increase by ~600 mcg every 4 weeks as tolerated (e.g., 0.6 → 1.2 → 1.8 → 2.4 mg; optional 3.6 → 4.8 mg) in line with dose ranges and escalation concepts used in trials[1][3]. Open source
Frequency: Once per week (subcutaneous).
Timing: Use a consistent weekly day/time; rotate injection sites.
Note: Slower escalations can mitigate GI adverse events such as nausea and diarrhea[3]. Open source

Storage Instructions

Proper storage preserves peptide stability.

Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions.
Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); protect from light; avoid repeated freeze–thaw.
Allow vials to reach room temperature before opening to reduce condensation.

Important Notes

Practical considerations for consistency and safety.

Use new sterile U‑100 insulin syringes; dispose in a sharps container.
Clean the vial stopper and skin with alcohol; allow to dry.
Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue; do not aspirate; inject slowly[4][5]. Open source
Rotate injection sites (abdomen, thighs, upper arms) to minimize local irritation/lipohypertrophy[6]. Open source
Document dose and site each week to maintain consistency.

How This Works

Survodutide activates GLP‑1 and glucagon receptors, supporting appetite control and increased energy expenditure. Preclinical work shows dual‑receptor engagement with weight‑lowering effects and a design enabling once‑weekly dosing[11]. Phase 2 trials in obesity used once‑weekly subcutaneous dosing with dose‑dependent weight loss[1], while studies in diabetes and liver disease further characterize efficacy and safety[3][12].

Lifestyle Factors

Complementary strategies for best outcomes.

Adopt a balanced, calorie‑appropriate diet emphasizing protein and whole foods.
Combine resistance and aerobic training to reinforce metabolic adaptations.
Prioritize sleep and stress management to support adherence.

Potential Benefits & Side Effects

Findings from clinical trials.

Benefits: Dose‑dependent weight reduction in individuals with overweight/obesity; glycemic improvements in type 2 diabetes cohorts[1][3]. Open source
Common side effects: GI symptoms (nausea, diarrhea, vomiting); typically mitigated by slower titration[3]. Open source
Overall tolerability: Acceptable in studied populations with monitoring and appropriate escalation[1][12]. Open source

Injection Technique

General subcutaneous guidance from authoritative sources[4][5][7].

Clean the vial stopper and skin with alcohol; allow to dry.
Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue; no aspiration[4][5]. Open source
Inject slowly and steadily; wait a few seconds before withdrawing.
Rotate sites (abdomen, thighs, upper arms) systematically to avoid local reactions[6]. Open source

Recommended Source

We recommend Prime Lab Peptides for Survodutide (10 mg).

High‑purity lots with third‑party testing and batch COAs.
Consistent documentation and careful handling.
Reliable fulfillment with appropriate packaging.

Important Note

This page is informational and does not authorize use. Peptify clients should complete assessment, disclose medications and health history, and follow the clinician-approved plan only.

Do not start, stop, combine, or change a protocol based only on website content.
Emergency symptoms require urgent medical care, not a website or routine follow-up message.

References